S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NASDAQ:XENE

Xenon Pharmaceuticals - XENE Stock Forecast, Price & News

$37.00
-0.45 (-1.20%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$36.43
$38.27
50-Day Range
$27.24
$39.68
52-Week Range
$14.65
$41.39
Volume
269,414 shs
Average Volume
486,186 shs
Market Capitalization
$2.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.83

Xenon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
29.3% Upside
$47.83 Price Target
Short Interest
Healthy
3.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.16mentions of Xenon Pharmaceuticals in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$6.98 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.10) to ($2.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

824th out of 1,116 stocks

Pharmaceutical Preparations Industry

416th out of 545 stocks

XENE stock logo

About Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Analyst Ratings Changes

XENE has been the topic of several research reports. Wedbush upped their price objective on shares of Xenon Pharmaceuticals from $41.00 to $50.00 in a research note on Wednesday, August 10th. JPMorgan Chase & Co. initiated coverage on shares of Xenon Pharmaceuticals in a research note on Thursday, July 21st. They issued an "overweight" rating and a $55.00 price objective on the stock. SVB Leerink upped their price objective on shares of Xenon Pharmaceuticals from $40.00 to $46.00 and gave the company an "outperform" rating in a research note on Thursday, August 11th. Finally, StockNews.com lowered shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $47.83.

Xenon Pharmaceuticals Stock Performance

Shares of XENE traded up $0.05 during mid-day trading on Friday, hitting $37.50. 3,902 shares of the company's stock were exchanged, compared to its average volume of 469,002. The firm has a fifty day moving average of $33.15 and a two-hundred day moving average of $31.32. Xenon Pharmaceuticals has a twelve month low of $14.65 and a twelve month high of $41.39.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of $0.54 million for the quarter, compared to the consensus estimate of $3.25 million. Xenon Pharmaceuticals had a negative return on equity of 17.33% and a negative net margin of 432.24%. Xenon Pharmaceuticals's quarterly revenue was down 75.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.51) earnings per share. Equities analysts expect that Xenon Pharmaceuticals will post -2.1 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Simon N. Pimstone sold 91,135 shares of the company's stock in a transaction on Friday, August 12th. The shares were sold at an average price of $38.28, for a total transaction of $3,488,647.80. Following the completion of the sale, the director now directly owns 92,000 shares of the company's stock, valued at approximately $3,521,760. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Xenon Pharmaceuticals news, Director Simon N. Pimstone sold 91,135 shares of the stock in a transaction on Friday, August 12th. The shares were sold at an average price of $38.28, for a total value of $3,488,647.80. Following the completion of the sale, the director now directly owns 92,000 shares of the company's stock, valued at approximately $3,521,760. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP James R. Empfield sold 57,743 shares of the stock in a transaction on Friday, August 12th. The shares were sold at an average price of $38.31, for a total transaction of $2,212,134.33. Following the completion of the sale, the executive vice president now directly owns 10,000 shares of the company's stock, valued at $383,100. The disclosure for this sale can be found here. In the last three months, insiders sold 182,820 shares of company stock valued at $6,982,432. Company insiders own 6.06% of the company's stock.

Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Stock News Headlines

4 Analysts Have This to Say About Xenon Pharmaceuticals
See More Headlines
Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Company Calendar

Last Earnings
8/09/2022
Today
8/19/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENE
Employees
149
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.83
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+29.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-78,880,000.00
Net Margins
-432.24%
Pretax Margin
-434.68%

Debt

Sales & Book Value

Annual Sales
$18.44 million
Book Value
$12.62 per share

Miscellaneous

Free Float
58,490,000
Market Cap
$2.30 billion
Optionable
Optionable
Beta
1.53

Key Executives

  • Mr. Ian C. Mortimer C.M.A. (Age 46)
    CPA, CMA, CPA, M.B.A., MBA, Pres, CEO & Director
    Comp: $957.16k
  • Ms. Sherry Aulin (Age 38)
    Chief Financial Officer
    Comp: $458.64k
  • Dr. Christopher John Kenney M.D.Dr. Christopher John Kenney M.D. (Age 51)
    Chief Medical Officer
    Comp: $494.83k
  • Ms. Jodi Regts M.B.A.
    B.A., MBA, VP of Corp. Affairs & Investor Relations
  • Ms. Shelley McCloskey B.A. (Age 62)
    Exec. VP of HR
  • Dr. Robin P. Sherrington Ph.D. (Age 61)
    Exec. VP of Strategy & Innovation
  • Dr. James R. Empfield Ph.D. (Age 61)
    Exec. VP of Drug Discovery
  • Ms. Sheila M. Grant M.B.A.
    M.Sc., MBA, Exec. VP of R&D Operations
  • Dr. Christopher E. Von Seggern M.B.A. (Age 43)
    M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer
  • Dr. Kenneth Sommerville
    Interim Chief Medical Officer













XENE Stock - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XENE shares.
View XENE analyst ratings
or view top-rated stocks.

What is Xenon Pharmaceuticals' stock price forecast for 2022?

7 analysts have issued 12 month price targets for Xenon Pharmaceuticals' stock. Their XENE share price forecasts range from $43.00 to $55.00. On average, they anticipate the company's share price to reach $47.83 in the next year. This suggests a possible upside of 29.3% from the stock's current price.
View analysts price targets for XENE
or view top-rated stocks among Wall Street analysts.

How have XENE shares performed in 2022?

Xenon Pharmaceuticals' stock was trading at $31.24 on January 1st, 2022. Since then, XENE stock has increased by 18.4% and is now trading at $37.00.
View the best growth stocks for 2022 here
.

When is Xenon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our XENE earnings forecast
.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.06. The biopharmaceutical company earned $0.54 million during the quarter, compared to analyst estimates of $3.25 million. Xenon Pharmaceuticals had a negative net margin of 432.24% and a negative trailing twelve-month return on equity of 17.33%. The firm's revenue was down 75.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.51) EPS.

What other stocks do shareholders of Xenon Pharmaceuticals own?
What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (7.34%), Driehaus Capital Management LLC (7.05%), Pictet Asset Management SA (3.43%), Commodore Capital LP (2.56%), Samlyn Capital LLC (1.79%) and Point72 Asset Management L.P. (1.45%). Insiders that own company stock include Christopher John Kenney, Frank A Holler, James R Empfield, Mohammad Azab, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends
.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $37.00.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.30 billion and generates $18.44 million in revenue each year. The biopharmaceutical company earns $-78,880,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

The company employs 149 workers across the globe.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.

This page (NASDAQ:XENE) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.